Personal Genome Diagnostics (PGDx) is an oncology company specializing in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomics.

PGDx is developing and commercializing a portfolio of tissue and liquid biopsy IVD cancer tests that will be clinically validated and regulated, and made available to clinical centers world-wide. Headquartered in Baltimore, PGDx is one of the premier life sciences companies in the region. It was established in 2010 by researchers from Johns Hopkins University who are among the world leaders in cancer genomics and in tissue-based and liquid biopsy technologies

‍